BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is happening in the market, especially within the growth sectors.

Immunovant, Inc. (NASDAQ:IMVT) is a biotechnology company that ranks eighth on our list of stocks expected to double in 2025. IMVT has a focus on developing advanced treatments for patients with ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) reached a new 52-week low on Monday after an insider sold shares in the company.The company traded as low as $22.35 and last traded at $22.38 ...

Immunovant, Inc. (NASDAQ:IMVT), a biopharmaceutical company specializing in biological products currently valued at $3.4 billion, has registered shares for resale by certain selling stockholders, ...